AstraZeneca Plans Production Rationalization and Job Cuts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca Plans Production Rationalization and Job Cuts


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

London (Feb. 1)—AstraZeneca PLC (www.astrazeneca.com) unveiled a plan to improve asset utilization within its global supply chain that involves rationalizing production assets and cutting staff. The company made the announcement as part of its fourth quarter and full-year 2006 financial results. 

Over the next three years, AstraZeneca plans to rationalize production assets, anticipating accounting charges of roughly $500 million, and reduce its workforce by 3000, subject to consultations with work councils, trade unions, and other employee representatives and in accordance with local labor laws. The company did not disclose which particular facilities would be affected.

“Going forward, management remains committed to maintaining a competitive financial performance during a period when the company, as well as the industry, faces the challenges imposed by patent expirations and pricing pressures from the government and private-sector players,” said the company in a prepared statement in explaining the rationale for the cost reductions.

For 2006, AstraZeneca reported an 11% sales gain to $26.5 billion and a 28% gain in profit to $6.04 billion.

AstraZeneca acquires biotech company

In another move, AstraZeneca agreed to acquire Arrow Therapeutics Ltd. (London, www.arrowt.co.uk), a privately held biotechnology company, for $150 million. Arrow Therapeutics is focused on the discovery and development of antiviral therapies. It has 57 employees at its facilities in London.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here